TY - A2的粉丝,达因AU - Wang Hui-Lian AU - Lu, Xi AU -杨,Xudong盟,徐奶奶PY - 2016 DA - 2016/09/08 TI -拉米耐药的慢性乙肝患者抗病毒治疗:系统回顾和荟萃分析SP - 3435965网络六世- 2016 AB -相对有效性的不同策略对慢性乙型肝炎(慢乙肝)患者拉米夫定耐药性(LAM-R)尚未系统研究。临床试验中搜索PUBMED、MEDLINE、EMBASE,和CNKI数据库到2016年2月15日。9个试验包括764例患者符合输入的标准。直接荟萃分析,TDF显示更强的抗病毒效应比任何ETV之一,林/副词和副词对LAM-R乙型肝炎病毒。林/副词疗法优于副词在抑制病毒复制。ETV实现类似的HBV DNA检测不到而难以或林/副词。在网络分析,TDF ETV相比较高的HBV DNA检测不到(OR, 24.69;95%置信区间:5.36 - -113.66)、副词(OR, 37.28;95%置信区间:9.73 - -142.92),或者林/副词(or, 21.05;95%置信区间:5.70 - -77.80)。 However, among ETV, ADV, and LAM/ADV, no drug was clearly superior to others in HBV DNA undetectable rate. Moreover, no significant difference in the rate of ALT normalization or HBeAg loss was observed compared the four rescue strategies with each other. TDF appears to be a more effective rescue therapy than LAM/ADV, ETV, or ADV. LAM plus ADV therapy was a better treatment option than ETV or ADV alone for patients with LAM-R. SN - 1687-6121 UR - https://doi.org/10.1155/2016/3435965 DO - 10.1155/2016/3435965 JF - Gastroenterology Research and Practice PB - Hindawi Publishing Corporation KW - ER -